Viridian Therapeutics, Inc.
VRDN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$269,949 | -$237,734 | -$129,874 | -$79,413 |
| Dep. & Amort. | $540 | $522 | $255 | $120 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $42,150 | $67,172 | $19,765 | $14,465 |
| Change in WC | $9,598 | -$9,425 | $15,962 | $1,724 |
| Other Non-Cash | -$14,658 | -$4,705 | $54 | $8,523 |
| Operating Cash Flow | -$232,319 | -$184,170 | -$93,838 | -$54,581 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$511 | -$898 | -$797 | -$338 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$695,068 | -$407,880 | -$223,264 | -$188,431 |
| Inv. Sales/Matur. | $466,928 | $314,526 | $108,935 | $114,398 |
| Other Inv. Act. | $0 | $0 | $0 | $79 |
| Investing Cash Flow | -$228,651 | -$94,252 | -$115,126 | -$74,292 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $15,000 | $5,000 | $0 |
| Stock Issued | $453,660 | $125,069 | $291,874 | $114,242 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $4,077 | $85,601 | $25,370 | $11,033 |
| Financing Cash Flow | $457,737 | $225,670 | $322,244 | $125,275 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$3,233 | -$52,752 | $113,280 | -$3,598 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $102,827 | $155,579 | $42,299 | $45,897 |
| End Cash | $99,594 | $102,827 | $155,579 | $42,299 |
| Free Cash Flow | -$232,830 | -$185,068 | -$94,635 | -$54,919 |